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Background: Array comparative genomic hybridization (a-CGH) has become the first-tier investigation in patients
with unexplained developmental delay/intellectual disability (DD/ID). Although the costs are progressively
decreasing, a-CGH is still an expensive and labour-intensive technique: for this reason a definition of the categories
of patients that can benefit the most of the analysis is needed. Aim of the study was to retrospectively analyze the
clinical features of children with DD/ID attending the outpatient clinic of the Mother & Child Department of the
University Hospital of Modena subjected to a-CGH, to verify by uni- and multivariate analysis the independent
predictors of pathogenic CNVs.
Methods: 116 patients were included in the study. Data relative to the CNVs and to the patients’ clinical features
were analyzed for genotype/phenotype correlations.
Results and conclusions: 27 patients (23.3%) presented pathogenic CNVs (21 deletions, 3 duplications and 3 cases
with both duplications and deletions). Univariate analysis showed a significant association of the pathogenic CNVs
with the early onset of symptoms (before 1 yr of age) and the presence of malformations and dysmorphisms.
Logistic regression analysis showed a significant independent predictive value for diagnosing a pathogenic CNV for
malformations (P = 0.002) and dysmorphisms (P = 0.023), suggesting that those features should address a-CGH
analysis as a high-priority test for diagnosis.
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The use of array-CGH (a-CGH) has recently become a
mainstay for the diagnosis of a broad spectrum of disor-
ders, including developmental delay/intellectual disability
(DD/ID), malformations and dysmorphisms, due to its
higher resolution power (about 100-fold) and diagnostic
yield (5- to 10-fold) compared with the classical karyotype
[1-3]. Large scale genomic analysis have highlighted a
pathogenic role for many copy number variations (CNVs),
which have been detected both in cases with syndromic* Correspondence: percesepe.antonio@unimo.it
†Equal contributors
2Medical Genetics Unit, Department of Mother & Child, University Hospital of
Modena, Via del Pozzo, 71, 41124 Modena, Italy
Full list of author information is available at the end of the article
© 2014 Caramaschi et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.features and in others lacking a clinical hallmark point-
ing to a specific genetic condition [4,5]. In addition,
about 12% of a healthy individual's genome can contain
a copy number variation whose role, if any, remains
unknown [6]. Dedicated on-line databases (DatabasE
of Chromosomal Imbalance and Phenotype in Humans
using Ensemble Resources – DECIPHER- http://decipher.
sanger.ac.uk; Database of Genomic Variants –DGV- http://
projects.tcag.ca/variation/), continuously expanded by the
scientific community, are providing growing information
to perform the genotype/phenotype correlations.
Although the costs are progressively decreasing, a-CGH
is still an expensive and labour- intensive technique, and
as such, cost-, clinical impact- and genotype/phenotype-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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correct indications to perform the analysis in selected cat-
egories of patients [7]. For example, the presence of patho-
genic CNVs has been correlated with a severe clinical
presentation or with a pleiotropic expression of the disease
[5,8,9]; other studies have demonstrated that the presence
of at least two clinical features increases the likelihood that
the phenotype is associated with CNVs [10], although
many exceptions exist, which underlie the extreme pheno-
typic heterogeneity of genomic disorders.
To highlight the most useful indications to perform the
a-CGH analysis in children with DD/ID and associated
clinical features (i.e. malformations, epilepsy, dysmorph-
isms), we report a retrospective study based on 116 con-
secutive cases referred to the Department of Mother &
Child of the University Hospital of Modena. The distribu-
tion of several clinical features was studied by univariate
and multivariate analysis in patients with vs. those without
pathogenic CNVs, to identify the strongest predictors of
the presence of genomic rearrangements and to recognize




Patients have been recruited at the outpatient Pediatric
Clinic of the Mother & Child Department of the Modena
University Hospital, in the years 2006–2013. The clinic
receives patients across the city area (about 600,000
inhabitants) and offers second-level assistance to the
Community Support Services. The outpatients are sequen-
tially evaluated by paediatricians, paediatric neurologists
and medical geneticists and their clinical information, in-
cluding previous personal and familial medical history, are
collected. Verification of the reported diagnosis is done
through the consultation of the medical records. Patients’
follow-up consists of annual clinical evaluations during
which the diagnostic process is carried out by using trad-
itional clinical and instrumental tools and genetic testing,
when appropriate.
The patients
For the purposes of the study we selected consecutive
paediatric patients undergoing a-CGH analysis for the
presence of DD/ID associated with at least one of the
following clinical features: 1) malformations, 2) epilepsy,
3) dysmorphisms. Malformations were defined as major
defects (i.e. those affecting organs like the heart, the uro-
genital tract), whereas isolated minor congenital anomalies
(i.e. persistent foramen ovale) were not considered for the
purposes of the study.
Clinical and genetic data obtained were retrospectively
collected in an Excel format database, including patient’s
records, pregnancy, neonatal and family histories, bodymeasurements, neurologic examination, brain imaging,
specialist opinions (eg. radiologist, surgeon), conventional
karyotype with a resolution of 550 bands for aploid set
[11] and a-CGH results (number, type, size, inheritance of
CNVs).
Array-CGH analysis
The Agilent 44 K platform was used for the analysis of all
patients, following manufacturer’s instructions (Agilent
Technologies). Briefly, 500 ng of patient and control
DNAs were double-digested with restriction enzymes
(AluI and RsaI) and differentially labeled with Cy-5 and
Cy-3, respectively. A “loop” strategy with three pheno-
typically different patients was used (for example A vs.
B, B vs. C and C vs. A). After hybridization on the 44 K
array, slides were washed and scanned. Agilent Feature
Extraction and Genomic Workbench softwares were used
to calculate log ratios, to create a graphical visualization of
the results and to call copy number aberrations (ADM-1
algorithm - threshold 6.0 -). Changes of 3 or more con-
secutive oligonucleotides with the same log ratio (dele-
tions about −1 or duplications about +0.5) were called
as CNVs. The loop strategy allowed the simultaneous
confirmation of each CNV, which had to be present in
two arrays of the loop with opposite values of log ratio
and the elimination of most of the polymorphic CNVs
with high frequency in the population.
CNVs were compared to the DECIPHER, DGV, ISCA
(International Standard for Cytogenomic Arrays consor-
tium, https://www.iscaconsortium.org/index.php/search)
and Troina Database of Human CNVs (http://gvarianti.
homelinux.net/gvariantib37/index.php) and classified pa-
thogenic, likely pathogenic, benign, likely benign or of
unknown significance, using the following criteria:
 pathogenic: anomalies mapping on genomic regions
associated to known syndromes or involving known
dosage-sensitive genes and large imbalances of de
novo origin or inherited from a similarly affected
parent;
 likely pathogenic: small alterations of de novo origin
or inherited from a parent with a similar phenotype,
involving genomic regions or genes whose possible
association with clinical conditions has not been
definitely identified, but could be supposed from the
clinical databases (DECIPHER, ISCA and Troina);
 benign: polymorphic variants reported in several
healthy individuals in more than one study within
DGV and/or alterations detected in at least two
patients with clearly distinct phenotypes of the
present cohort;
 likely benign: microdeletions and microduplications
reported in few controls in DGV, but defined benign
or likely benign in the clinical databases
Table 2 Type, number, size and inheritance of the CNVs







N = 27 N = 12 N = 2
Type
Deletion 21 (77.8%) 2 (16.7%)
Duplication 3 (11.1%) 9 (75.0%) 2 (100%)
Duplication and
deletion
3 (11.1%) 1 (8.3%)
No. CNVs
1 22 8 2
≥2 5 4
Size
≤0.5 Mb 6 (50%) 2 (100%)
>0.5 Mb 27 (100%) 6 (50%)
Inheritance
De novo 21 (77.8%) 1 (8.3%)
Familial 5 (18.5%) 7 (58.3%) 2 (100%)
Unknown 1 (3.7%) 4 (33.3)
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a normal parent;
 of unknown significance: inherited alterations not
described or with discordant definitions among
those databases [12].
Statistical analysis
Patients were stratified according to the presence of
several clinical features, all potentially related to the
presence of a pathological phenotype (positive family
history, delivery before 37 gestational weeks, apgar
score <7, low birth weight – less than the fifth centile-,
early onset of symptoms (<1 year of age), motor delay,
dysmorphisms, malformations –brain excluded-, speech
delay, epilepsy, cerebral malformations), converting de-
scriptive variables into numerical. For the purposes of
the analysis pathogenic and likely pathogenic CNVs
were grouped together. The relationship between each
variable and the presence of pathogenic CNVs was first
analyzed by means of univariate analysis (chi-squared
for 2-by-2 tables). Furthermore, in order to identify the
independent predictors of the diagnosis of pathogenic
CNVs, the variables resulting significant at the univariate
analysis were subjected to logistic regression, using the
presence of pathogenic CNVs as a dependent dichot-
omous variable [13], and odds ratios and their 95% con-
fidence intervals (CI) were calculated. Results were
considered statistically significant for p < 0.05. Statistical
analyses were carried out with STATA software (version
11.1, 2010; StataCorp, College Station, TX, USA).
The study was approved by Modena Institutional Review
Board (Protocol No. 249/12, 5th March 2013).
Results
Out of the 116 patients (58 males and 58 females) sub-
jected to a-CGH analysis, 111 had a normal and 5 an
abnormal karyotype (in those latter cases a-CGH was
used to characterize the genomic alteration). Abnormal
karyotypic findings are listed in Table 1.
Table 2 shows the number, type, inheritance and clinical
interpretation of the CNVs found in the study population:
41 patients showed at least one CNV, whereas 75 did notTable 1 Abnormal karyotypes found in patients who








For their a-CGH results refer to Table 3.show any. Twenty-seven out of 41 patients carried a
pathogenic (or likely pathogenic) CNV, whereas 12 had a
benign one. In 2 unrelated cases (both had a 489 Kb dupli-
cation in 15q13.3 of maternal inheritance) the role of the
CNV found is unknown. The genomic details of the
pathogenic CNVs and their clinical correlates are listed in
Table 3.
By comparing the frequency of each clinical feature in
patients with pathogenic vs. those with benign or absent
CNVs (the 2 cases with CNVs of unknown interpretation
were excluded), a statistically significant association with
the presence of pathogenic CNVs was found for the
early onset of symptoms (p = 0.027), the presence of dys-
morphisms (p = 0.003) and malformations (p = 0.0001),
whereas all the other variables did not show any statis-
tical significance (Figure 1).
The clinical variables found to be associated with
pathogenic CNVs were further analyzed by a multivari-
ate analysis and a statistically significant odds ratio for
association with pathogenic CNVs was confirmed for the
presence of dysmorphisms (p = 0.023) and malforma-
tions (p = 0.002), whereas the onset of symptoms before
the first year of age was not (p = 0.069) (Table 4).Discussion
The use of a-CGH in the clinical settings has been
shown to improve the follow-up, the rehabilitation strat-
egies and, in selected cases, the prophylactic therapy in
patients in which the presence of pathogenic CNVs is
demonstrated [17,18].
Table 3 List of genomic rearrangements in patients with pathogenic CNVs
Patient No. Sex Type Locus Genomic coordinates Inheritance Syndrome OMIM
1 M del 1p36.33p36.31 chr1:837,491-6,458,739 de novo 1p36.33 deletion S. 607872
2 F del 1p36.33p36.31 chr1:544,268-5,983,997 de novo 1p36.33 deletion S. 607872
3 F del 1p36.22p36.13 chr1:11,722,823-17,104,536 de novo -
del 1p35.1p34.1 chr1:31,080,722-32,355,071 de novo -
4 F del 1q23.3q24.2 chr:162,345,741-169,317,061 de novo -
5 F del 1q41 chr1:217,316,641-218,402,514 not known 1q41-1q42 deletionS. 612530
del 6q24.2 chr6:144,223,274-144,446,997 not known -
6 Ref [14] M dup 1q42qter chr1:223,858,274-248,105,710 de novo -
7 F del 2q14.3 chr2:125,049,268-129,322,082 de novo -
8 F del 2q24.3 chr2:166,198,780-166,930,047 de novo -
9 M dup 4p15.32 chr4:26,509-27,414 de novo -
del 17q24.2 chr17:64,682,538-65,991,538 de novo -
10 M del 4q26q28.1 chr4:117,685,833-127,471,713 de novo -
11 M dup 4q33q35.1 chr4:171,936,073-186,883,667 de novo -
del 4q35.1q35.2 chr4:186,913,016-190,976,417 de novo -
12 Ref [15] M del 5p15.33p15.32 chr5:22,178-5,539,182 paternal Cri du Chat S. 123450
13 F del 5q14.3q15 chr5:89,535,781-92,554,566 de novo -
14 M del 5q23.2q31.1 chr5:124,391,181-134,632,894 de novo -
15 F del 6q27 chr6:168,378,740-169,862,121 de novo -
16 M del 7q11.23 chr7:72,039,051-73,771,238 de novo Williams-Beuren S. 194050
17 M del 7q21.13q21.3 chi7:89,993,838-96,278,971 de novo Split Hand Foot Malformation 1
with sensorineural hearing loss
220600
18 M del 7q31.1q31.2 chr7:113,824,764-115,669,764 de novo -
19 F del 7q36 chr7:153,669,067-159,107,239 de novo Holoprosencephaly-3 142945
20 F del 15q13.2q13.3 chr15:31,014,000-32,510,000 maternal -
21 F del 15q26.3 chr15:99,836,103-102,351,195 paternal 15q26-qter deletion S. 612626
22 F dup 16p13.11p12.3 chr16:15,492,317-17,804,366 maternal -
23 F del 17q12 chr17:31,891,355-33,726,698 de novo 17q12 deletion S 614527
24 M del 19p13.3 chr19:64,447-721,353 de novo -
25 Ref [16] M dup 19q12q13.2 chr19:28,272,160-40,699,160 de novo -
26 M del 22q13.31 chr22:45,576,757-51,178,264 de novo Phelan Mc Dermid S. 606232
dup Xq28 chrX:153,322,653-153,406,233 de novo -
27 F del 22q11.21 chr22:19,375,985-21,382,953 maternal DiGeorge S. 188400
Genomic coordinates refer to Human Genome Assembly (Hg 19). If the analysis was performed with previous assemblies, data were converted in Hg 19. M =male,
F = female, del = deletion, dup = duplication.
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System of the Emilia-Romagna Region has introduced
a-CGH in the list of reimbursable tests only in 2013 and
the network of laboratories in the Region is still organ-
izing to offer the analysis with short waiting lists and
lead times. For all these reasons, understanding which
patients and families may benefit the most is required
and clinical predictors are needed. Although evidence
already exists to offer a-CGH as a first-tier exam in pa-
tients showing ID with or without additional clinical
features [1], further data have shown that patients withsyndromic ID (multiple congenital anomalies) or with
severe phenotypes have a higher likelihood to be car-
riers of CNVs [10].
In our study, the relative burden conveyed by each
feature accompanying DD/ID was evaluated by a multi-
variate analysis on 116 patients in which the frequency
of several clinical variables referring to the pregnancy,
delivery, family history, associated malformations, psycho-
motor development and dysmorphisms were compared
between patients showing pathogenic CNVs vs. all the
others (those negative and with benign CNVs).
Figure 1 Clinical features of the patients under study according to the presence of pathogenic CNVs. For each variable the number (n=), the
percentage of patients (in parenthesis) and the P values (in boxes) are reported. Statistical significance is indicated with the presence of an asterisk.
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and a pathogenic role was attributed in 27 cases (23.3%
of the study population). Among those latter, 21 had a
de novo rearrangement, 5 were inherited (Table 3) (the
transmitting parent always displayed some degree of
phenotype) and 1 was of unknown origin. On the other
hand, among the benign CNVs carriers only 1 patient
presented a de novo rearrangement, a 500 Kb interstitial
duplication in 14q11.2 of unequivocal interpretation, due
to the high frequency (>3%) in the normal population
[19]. Deletions were 85% of the pathogenic CNVs, consist-
ent with the notion that haploinsufficiencies are less toler-
ated than duplications in the human genome [20].
When analysing the clinical features associated with
DD/ID and their relative frequency in patients with or
without pathogenic CNVs, no difference emerged for
birth-related variables, delay in motor or language devel-
opment or for brain malformations and epilepsy (Figure 1),
which are possibly attributable also to different aetiologies
(i.e. monogenic or multifactorial), due to their high genetic
heterogeneity. On the other hand, the onset of symptomsTable 4 Multivariate analysis for the clinical features
significantly associated to the pathogenic CNVs at the
univariate analysis
Clinical variables Odds ratio Std. Err. P [95% conf.
interval]
Early onset of symptoms
(before 1 yr of age)
2.567 1.331 0.069 0.930 - 7.090
Dysmorphisms 3.326 1.752 0.023 1.184 - 9.340
Malformations 5.365 2.871 0.002 1.880 - 15.312before one year of life (p = 0.027), the presence of malfor-
mations (p = 0.0001) and of dysmorphisms (p = 0.003)
resulted significantly associated to the pathogenic CNVs
at the univariate analysis (Figure 1), confirming previous
data referred to other European populations [10]. When
subjected to logistic regression analysis, the dysmorphisms
(p = 0.023) and the malformations (p = 0.002) emerged as
independent predictors of diagnosing a pathogenic CNV
in children with DD/ID, whereas the early onset of symp-
toms, an additional indicator of the gravity of the pheno-
type encompassing neonatal hypotonia, infantile epilepsy
and motor delay, failed to show a significant result, pos-
sibly due to a type 2 statistical error caused by the low
number of observations.
Our results confirm that severe phenotypes character-
ized by the presence of malformations and dysmorphisms
associated with DD/ID are causally related to the presence
of CNVs, as previously demonstrated [10,21]; moreover,
the analysis predicts the likelihood to detect a pathogenic
genomic alteration, attributing a 3.3-fold increase to the
presence of dysmorphic features and a 5.3-fold to the
malformations (Table 4), thus reaffirming the import-
ance of a thorough phenotypic characterization of the
patients undergoing a-CGH analysis for maximizing the
results [10].
Conclusions
In conclusion, dissecting the phenotype of children with
DD/ID undergoing a-CGH led us to identify the malfor-
mations and the dysmorphisms as independent clinical
predictors for finding pathogenic CNVs, indicating that
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should address a-CGH analysis as a high-priority test for
diagnosis.
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